Buy Out Perspective Of A Clinical Trials Professional
As a seasoned Clinical Trials Physician of 30+ years, I had to ask myself looking at the "BIG PICTURE", does the CEO really want ALL this responsibility on his back of running this company after all the decades of work he has done, when it would be FAR better for him to simply SELL RGBP to the highest Big Pharma bidder so he can move on with his life in his retirement years. I know I would!
He's done A LOT to get RGBP to where it is today, and I can almost sense his strong desire to pass it all on to a Big Pharma that has the infrastructure, big bucks, man power, and expansive resources to bring most, if not ALL his valuable Candidate Drug Patents to Market, possibly even building upon his original science associated with each Patent! Does he really want the intense prospect of this at his age??
I can tell you this, if I were him this is exactly what I would do at this point in my life! I believe I'm "reading him" loud & clear based on these last two filings he made, and I'm qualified to make this type of assessment due to me being a clinical trials career professional knowing the enormous time, energy, logistics, and expense that involves bringing an IND Patent to Market. It's extremely time consuming, labor intensive, and expensive!
He has already "done his job" and he has done it well with the extensive portfolio of Billion Dollar market capacity Candidate Drug Patents he has to his name. I discern he's in the process of selling it all and it wouldn't surprise me at all if the buyer is Eli Lilly since they have a history of collaboration. I think this explanation is an accurate one and we're witnessing it all unfold!
If I'm right, a Buy Out will be announced within weeks to months of him 1). Bringing RGBP fully SEC compliant with full disclosures, and 2). ALL his outstanding viable expired Patents renewed to current IND Status that an acquiring Big Pharma could place immediately in their clinical trials pipeline.
He has to bring all this together simultaneously that shouldn't take more than 6 months max, and likely he's already entered into buy out discussions behind the scenes with various Big Pharmas.
I believe by this time next year RGBP will have already been acquired by a Big Pharma for $1.50-$3.00 per Share, and then all current RGBP shareholders Shares will be trading at the PPS of the acquiring Big Pharma adjusted on a ratio relative to the value of the underlying shares.
What this means is you would end up with fewer shares but all of them would be worth much more than what you paid for them. I would rather have 50% of the shares I currently own that are worth 10X to 50X more than what I paid for them. This is only an illustration, nothing more.
My final take is that within weeks of the CEO bringing this company Pink Current with full disclosures, a formal Buy Out offer by a Big Pharma will be made and accepted toward the end of this year (i.e. 6 months out from now), or early next year 1st Quarter!
Again all of this is only an opinion but it's a career clinical trials professional's opinion who fully comprehends what's involved.
Be well and prosper...
